VPPM — ProFund VP Pharmaceuticals
Data updated: 2026-05-20
VPPM — ProFund VP Pharmaceuticals data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $10.17M AUM · 1.68% expense ratio · 21.9% 1-yr return. From SEC regulatory filings.
VPPM Fund Overview
VPPM — ProFund VP Pharmaceuticals is a US mutual fund managed by ProFunds, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: ProFunds
- Category: United States Health Care Equity
- Assets under management: $10.17M
- 1-year return: 21.9%
- Ticker: VPPM
- SEC CIK: 0001039803
- SEC series ID: S000003975
- Share class ID: C000011102
VPPM Holdings
Top 10 holdings of ProFund VP Pharmaceuticals by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Enliven Therapeutics Inc | 2.35% |
| Corcept Therapeutics Inc. | 2.20% |
| Terns Pharmaceuticals Inc. | 2.08% |
| Perrigo Company PLC | 2.02% |
| Axsome Therapeutics Inc. | 1.95% |
| Innoviva Inc | 1.91% |
| Merck & Co., Inc | 1.91% |
| Pfizer Inc. | 1.89% |
| Royalty Pharma PLC | 1.89% |
| Elanco Animal Health Inc | 1.88% |
VPPM Portfolio Allocation
Asset-class allocation of ProFund VP Pharmaceuticals by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 96.0% |
| Cash & Equivalents | 3.9% |
| Derivatives | 0.1% |
VPPM Performance
Total returns for VPPM (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -4.0% |
| 1 year | 21.9% |
| 3 years (annualised) | 9.2% |
| 5 years (annualised) | 5.1% |
VPPM Risk Information
Risk metrics for VPPM, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 20.6%
VPPM Costs and Fees
VPPM costs about $168 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.68%
- Gross expense ratio: 1.69%
- Portfolio turnover: 143%
- Brokerage commissions: 3.51 bps of average net assets (SEC N-CEN)
VPPM Cashflows
Over the 12 months to 2026-03, ProFund VP Pharmaceuticals had net outflows of $495.32K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$3.85K |
| 2026-02 | $28.86K |
| 2026-01 | $77.34K |
| 2025-12 | −$594.88K |
| 2025-11 | $686.15K |
| 2025-10 | −$403.20K |
VPPM Debt Constituents
No individual debt constituents are reported in ProFund VP Pharmaceuticals's latest SEC N-PORT filing.
VPPM Prospectus and SEC Filings
Official ProFund VP Pharmaceuticals filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.